Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum

Journal of Lipid Research

Volumn 52, Issue 6, 2011, Pages 1265-1271

  Wang, Yuxin ^a   Song, Zhili ^a   Wagner, Janice D ^b   Pachuk, Catherine ^a   Subramanian, Romesh R ^a  

^a PFIZER INC   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoproteins; Dyslipidemias; Enzymology; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CP 900691; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALIBRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HAPLORHINI; LIMIT OF DETECTION; LIPID ANALYSIS; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; MACACA FASCICULARIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTRIGLYCERIDEMIA; LIMIT OF DETECTION; MACACA FASCICULARIS; MALE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79955984456     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D011148     Document Type: Article

References (18)

1. Bobik, A. 2008. Apolipoprotein C-III and atherosclerosis, beyond effects on lipid metabolism. Circulation. 118: 702-704.
2. Caron, S., and B. Staels. 2008. ApoCIII: a link between hypertriglyceridemia and vascular dysfunction? Circ. Res. 103: 1348-1350.
3. Fredenrich, A. 1998. Role of apolipoprotein CIII in triglyceriderich lipoprotein metabolism. Diabetes Metab. 24: 490-495.
4. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apoc-III gene expression in transgenic mice. Science. 249: 790-793.
5. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
6. Herbert, P. N., L. L. Bausserman, K. M. Lynch, A. L. Saritelli, M. A. Kantor, R. J. Nicolosi, and R. S. Shulman. 1987. Homologues of the human C and A apolipoproteins in the Macaca fascicularis (cynomolgus) monkey. Biochemistry. 26: 1457-1463.
7. Osada, J., M. Pocovi, R. J. Nicolosi, E. J. Schaefer, and J. M. Ordovas. 1993. Nucleotide sequences of the Macaca fascicularis apolipoprotein C-III and A-IV genes. Biochim. Biophys. Acta. 1172: 335-339.
8. Onat, A., G. Hergenc, E. Ayhan, M. Ugur, H. Kaya, M. Tuncer, and G. Can. 2009. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet. Med. 26: 981-988.
9. Kashyap, M. L. 1996. Immunochemical methods for quantification of human apolipoprtein CIII. Methods Enzymol. 263: 208-218.
10. Bury, J., and M. J. Rosseneu. 1985. Enzyme-linked immunosorbent assay (ELISA) development for human Apolipoprotein C-III. J. Clin. Chem. Clin. Biochem. 23: 63-79.
11. Wagner, J. D., M. K. Shadoan, L. Zhang, G. M. Ward, L. J. Royer, K. Kavanagh, O. L. Francone, B. J. Auerbach, and H. J. Jr.Harwood. 2010. A selective PPAR a agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J. Pharmacol. Exp. Ther. 333: 844-853.
12. Chakrabarti, R., R. K. Vikramadithyan, P. Misra, J. Hiriyan, S. Raichur, R. K. Damarla, C. Gershome, J. Suresh, and R. Rajagopalan. 2003. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br. J. Pharmacol. 140: 527-537.
13. Clavey, V., C. Copin, M. C. Mariotte, E. Bauge, G. Chinetti, J. Fruchart, J. C. Fruchart, J. Dallongeville, and B. Staels. 1999. Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell. Physiol. Biochem. 9: 139-149.
14. Schultze, A. E., W. E. Alborn, R. K. Newton, and R. J. Konrad. 2005. Administration of a PPAR-a agonist increases serum apolipoprotein A5 levels and the apolipoprotein A5/Apolipoprotein C3 ratio. J. Lipid Res. 46: 1591-1595.
15. Qu, S., D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, and H. H. Dong. 2006. PPARa mediates the hypolipidemic action of fifibrates by antagonizing FoxO1. Am. J. Physiol. Endocrinol. Metab. 292: E421-434.
16. Winegar, D. A., P. J. Brown, W. O. Wilkison, M. C. Lewis, R. J. Ott, W. Q. Tong, H. R. Brown, J. M. Lehmann, S. A. Kliewer, K. D. Plunket, et al. 2001. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J. Lipid Res. 42: 1543-1551.
17. Jackson, R. L., and G. Holdsworth. 1986. Isolation and properties of human apolipoproteins C-1, C-II and C-III. Methods Enzymol. 128: 288-297.
18. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.